中文
FROM CRITICAL EQUIPMENT TO
TOTAL PROCESS SOLUTION
Pharmadule Morimatsu AB Delivers EIPICO’s First Modular Biopharmaceutical Plant in Egypt, Establishing a New Hub for Pharmaceutical Innovation
Time:2025-07-18 15:12:31

Recently, Pharmadule Morimatsu AB successfully delivered the landmark EIPICO3 Modular Pharmaceutical Plant project. The successful completion of this project marks the perfect inauguration of Egypt's first modular biopharmaceutical plant integrating mixed production and filling functions for monoclonal antibodies and small molecule proteins, setting a new benchmark.

As one of the core pharmaceutical markets in the Middle East and North Africa region, Egypt has long faced the challenge of heavy reliance on imported biological products. EIPICO, a leading enterprise in Egypt's pharmaceutical sector, partnered with Pharmadule Morimatsu AB to build this advanced modular plant, which will bridge the technological gap in Egypt's high-end biopharmaceutical production and inject strong momentum into the development of the local healthcare industry.

1.jpg

In the early stages of the project, the joint participation of the design and project teams enhanced execution efficiency and controllability. All structural elements of the modules were manufactured in Pharmadule Morimatsu AB’s workshops in China before being shipped to Egypt for installation. Leveraging robust overall planning and design capabilities, as well as supply chain coordination and manufacturing proficiency, Pharmadule Morimatsu AB completed the production of 88 highly integrated modules in just 100 days. These modules encompassed critical facilities such as cleanrooms, process equipment, piping systems, ventilation systems, electrical controls, BMS&EMS management systems, fire alarm systems, and security systems. The on-site construction phase was equally efficient, with all 88 modules installed in 21 days, followed by successful Site Acceptance Testing (SAT) and system commissioning verification.

 

EIPICO Executives Visit the Project Site

Mr. Ahmed Kelani, Chairman and General Manager of EIPICO, spoke highly of Pharmadule Morimatsu AB, praising it as a "trustworthy and outstanding partner." He emphasized that Pharmadule Morimatsu AB possesses an exceptional and highly professional project team, consistently adhering to the highest industry standards and delivering outstanding quality. This has laid a solid foundation for deepening strategic collaboration and expanding future cooperation between both parties.

With the deepening advancement of the Belt and Road Initiative, trade cooperation between China and Egypt, as well as the broader African region, continues to strengthen. The successful completion of the EIPICO3 modular pharmaceutical plant not only marks a significant step forward for Egypt in the high-end biopharmaceutical sector but also stands as a fruitful achievement of China-Egypt cooperation under the Belt and Road framework. Pharmadule Morimatsu AB, in collaboration with EIPICO, is strengthening the foundation of Egypt's pharmaceutical and healthcare industry, opening a new chapter in making more accessible and higher-quality biopharmaceuticals available to the public, and jointly building a global model for a healthier future.


About Morimatsu LifeSciences

Morimatsu Life Sciences is one of the key business segments of Morimatsu International Holdings Company Limited (Morimatsu International, Stock Code: 2155.HK). It primarily consists of Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Company Limited, Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai MoriSora Technology Co., Ltd., and Pharmadule Morimatsu AB, along with their subsidiaries.

We specialize in providing core equipment, process systems, and comprehensive digital-intelligent plant solutions along with corresponding services for industries including pharmaceuticals, biopharmaceuticals, medical aesthetics, fast-moving consumer goods (FMCG, including cosmetics, food, health products, etc.), and data centers. The company boasts an elite team composed of seasoned experts across multiple fields, including process R&D, engineering design, high-end manufacturing, validation consulting, production execution, and digital-intelligent operations. The team members possess extensive experience in industries such as pharmaceuticals, biopharmaceuticals, medical aesthetics, FMCG, and data centers. They are well-versed in the characteristics and process flows of diverse products, enabling them to provide customized process solutions tailored to client needs from the conceptual design stage onward.

Morimatsu LifeSciences has established a global strategic presence, with advanced R&D, design centers, and manufacturing bases across different countries and regions, complemented by a comprehensive service network covering Europe, America, Asia-Pacific, and emerging markets. The company's international professional team has successfully delivered customized solutions to over 40 countries and regions, accumulating rich experience in global project execution.

As a multinational enterprise mastering core process technologies, modular construction, and digital-intelligent plant expertise, Morimatsu LifeSciences is committed to meeting the production equipment demands of global industries, including pharmaceuticals, biopharmaceuticals, medical aesthetics, FMCG, and data centers. Through continuous innovation and optimization, the company supports domestic enterprises in accelerating the strategic localization of core and high-end equipment, driving industry advancement. Simultaneously, the company actively expands overseas markets, deepening its "globalization" business development strategy to contribute Morimatsu's expertise to the global life sciences and related industries.